Adaptimmune Therapeutics plc (ADAP) 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adaptimmune Therapeutics plc (“Adaptimmune” or the “Company”) (NASDAQ: ADAP). Investors who purchased Adaptimmune shares are encouraged to obtain additional information and assist the investigation.        

The investigation concerns whether Adaptimmune has violated federal securities laws.

On September 9, 2022, Adaptimmune issued a press release announcing new data from its Phase 1 SURPASS trial for anti-cancer agent ADP-A2M4CD8 in patients with solid tumors.  Among other results, the press release disclosed that “[a]mong adverse events (AEs) of special interest: 32 people (73%) had cytokine release syndrome (CRS); most events were low grade and resolved (~86% ≤ Grade 2).  Eleven people (25%) had cytopenia (Grade ≥3) at 4 weeks after treatment.  Three people (7%) had Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) related to ADP-A2M4CD8.”  The press release also stated that “[t]here were 2 deaths reported as related to ADP-A2M4CD8 by investigators.  A 60-year-old woman with ovarian cancer with a large tumor burden in her lungs died due to pneumonia and CRS” and “a 71-year-old man with adenocarcinoma of the esophagus and a history of chronic anemia died due to bone marrow failure.”  On this news, Adaptimmune’s stock price fell $0.12 per share, or 5.88%, to close at $1.92 per share on September 9, 2022. 

If you are aware of any facts relating to this investigation or purchased Adaptimmune shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.  The firm has recovered hundreds of millions of dollars for investors nationwide.  Attorney advertising. Prior results do not guarantee similar outcomes.